These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34114645)

  • 1. Successful management of treatment resistant nail psoriasis with tildrakizumab.
    Simpson K; Low ZM; Howard A; Kern JS
    Australas J Dermatol; 2021 Aug; 62(3):390-393. PubMed ID: 34114645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nail Psoriasis Improvement During Tildrakizumab Therapy: A Real-Life Experience.
    Brunasso A
    J Drugs Dermatol; 2022 Aug; 21(8):914-916. PubMed ID: 35946963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
    Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
    J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.
    Reich K; Sullivan J; Arenberger P; Mrowietz U; Jazayeri S; Augustin M; Parneix A; Regnault P; You R; Milutinovic M
    Br J Dermatol; 2019 Nov; 181(5):954-966. PubMed ID: 30367462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.
    Elewski BE; Baker CS; Crowley JJ; Poulin Y; Okun MM; Calimlim B; Geng Z; Reyes Servin O; Rich PA
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):2168-2178. PubMed ID: 31304993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting.
    Bhatia N; Heim J; Vasquez JG; Bhutani T; Schenkel B; Gogineni R; Koo J
    J Dermatolog Treat; 2024 Dec; 35(1):2310631. PubMed ID: 39038815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
    Blauvelt A; Sofen H; Papp K; Gooderham M; Tyring S; Zhao Y; Lowry S; Mendelsohn A; Parno J; Reich K
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tildrakizumab for the treatment of psoriasis.
    Sinclair R; Thirthar Palanivelu V
    Expert Rev Clin Immunol; 2019 Jan; 15(1):5-12. PubMed ID: 30394141
    [No Abstract]   [Full Text] [Related]  

  • 9. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
    Langley RG; Rich P; Menter A; Krueger G; Goldblum O; Dutronc Y; Zhu B; Wei H; Cameron GS; Heffernan MP
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis.
    Galluzzo M; Talamonti M; Cioni A; Maffei V; Shumak RG; Tofani L; Bianchi L; Campione E
    J Clin Med; 2022 May; 11(9):. PubMed ID: 35566756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study.
    Nash P; Mease PJ; Kirkham B; Singhal A; Quebe-Fehling E; Pricop L; Gaillez C
    Clin Exp Rheumatol; 2022 May; 40(5):952-959. PubMed ID: 34494957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study.
    Patsatsi A; Kyriakou A; Sotiriadis D
    J Dermatolog Treat; 2013 Apr; 24(2):96-100. PubMed ID: 21797806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients.
    Drerup KA; Seemann C; Gerdes S; Mrowietz U
    Dermatology; 2022; 238(4):615-619. PubMed ID: 34775387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.
    Ter Haar ELM; Van den Reek JMPA; Gaarn Du Jardin K; Barbero-Castillo A; De Jong EMGJ; Lubeek SFK
    Acta Derm Venereol; 2023 Oct; 103():adv17752. PubMed ID: 37877618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 52-Week Mid-term Efficacy of Tildrakizumab in Moderate-to-severe Psoriasis: A Real-life Multicenter Experience.
    Melgosa Ramos FJ; Mateu Puchades A; Matáix-Díaz J; Schneller-Pavelescu L; Belinchón-Romero I; Santos Alarcón S
    Actas Dermosifiliogr; 2024; 115(7):722-726. PubMed ID: 38556201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.
    Bardazzi F; Starace M; Bruni F; Magnano M; Piraccini BM; Alessandrini A
    Acta Derm Venereol; 2019 May; 99(6):516-523. PubMed ID: 30521057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
    Papp K; Thaçi D; Reich K; Riedl E; Langley RG; Krueger JG; Gottlieb AB; Nakagawa H; Bowman EP; Mehta A; Li Q; Zhou Y; Shames R
    Br J Dermatol; 2015 Oct; 173(4):930-9. PubMed ID: 26042589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab efficacy in the treatment of nail psoriasis: a case series.
    Pistone G; Gurreri R; Tilotta G; Castelli E; Bongiorno MR
    J Dermatolog Treat; 2018; 29(sup1):21-24. PubMed ID: 30273068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
    Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y;
    Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2).
    Menter MA; Mehta NN; Lebwohl MG; Gottlieb AB; Mendelsohn AM; Rozzo SJ; Leonardi C
    J Drugs Dermatol; 2020 Aug; 19(8):703-708. PubMed ID: 32845115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.